Overview

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Status:
Unknown status

Trial end date:
2014-07-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to compare the efficacy and safety of tesetaxel administered once every 3 weeks in a 21-day cycle, tesetaxel administered once weekly for 3 consecutive weeks in a 28-day cycle, and capecitabine administered twice daily for 14 consecutive days in a 21-day cycle.

Phase:

Phase 2

Details

Lead Sponsor:

Genta Incorporated

Treatments:

Capecitabine